Use of Upadacitinib to Treat Atopic Dermatitis Refractory to Dupilumab in Elderly Patients
Main Article Content
Keywords
atopic dermatitis, dupilumab, upadacitinib, elderly, refractory atopic dermatitis, JAK inhibitor
Abstract
Atopic dermatitis (AD) is a relapsing and remitting inflammatory skin disease that can significantly impair an individual’s quality of life. Elderly-onset AD is increasing in prevalence in developed countries, likely due to aging populations. When disease is refractory to both topical steroids and dupilumab (a systemic IL-4R α inhibitor), there remains a lack of guidelines for treatment in elderly populations. Herein, we describe the treatment of five elderly patients (≥ 65-years-old) with upadacitinib, a novel JAK-inhibitor that is rarely used in elderly patients due to the elevated risk of systemic side effects. In this report, we found that upadacitinib successfully treated these patients’ atopic dermatitis, with minimal adverse effects. Presently, all five patients continue with this treatment.
References
2. Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic Dermatitis in Adults: A Diagnostic Challenge. J Investig Allergol Clin Immunol. 2017;27(2):78-88. doi:10.18176/jiaci.0138
3. Tanei R. Clinical Characteristics, Treatments, and Prognosis of Atopic Eczema in the Elderly. J Clin Med. 2015;4(5):979-997. Published 2015 May 18. doi:10.3390/jcm4050979
4. Kanwar AJ. Adult-onset Atopic Dermatitis. Indian J Dermatol. 2016;61(6):662-663. doi:10.4103/0019-5154.193679
5. Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatol Ther (Heidelb). 2017;7(1):1-23. doi:10.1007/s13555-016-0170-1
6. Gade A, Ghani H, Rubenstein R. Dupilumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 2, 2023.
7. Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86(3):628-636. doi:10.1016/j.jaad.2021.06.017
8. Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging. 2020;37(3):149-160. doi:10.1007/s40266-020-00750-5
9. Navarro-Triviño F, Alcantara-Luna S, Domínguez-Cruz J, et al. Upadacitinib for moderate to severe atopic dermatitis. Immunotherapy. 2023;15(11):799-808. doi:10.2217/imt-2023-0037
10. Piscazzi F, Gargiulo L, Ibba L, et al. Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients. J Dermatolog Treat. 2023;34(1):2245510. doi:10.1080/09546634.2023.2245510
11. Padda IS, Bhatt R, Parmar M. Upadacitinib. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 3, 2023.
12. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-744. doi:10.1016/j.jaad.2016.12.005
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.